Transformative Biotech LLC, a Boulder-based company working to develop faster molecular tests for diseases such as COVID-19 and cancer, has appointed Mark Kelleher as executive vice president of ...
With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter, ...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive ...
At the end of 2025, as part of a bundle of measures to make the EU health sector more innovative, competitive and resilient, the European Commission proposed the EU Biotech Act (the Act) aimed at ...
The National Security Commission on Emerging Biotechnology (NSCEB) delivered its major report and action plan to Congress in early April with a blunt message: the world is entering a new age driven by ...
What emerged through such discussions was not optimism nor was it pessimism, but clarity. The consensus was striking in its consistency across sessions. JPM 2026 signalled genuine recovery – but not ...
Entering plant-based biotechnologies to advance Robertet’s "Augmented Naturality” strategy Strengthening Robertet’s position ...
Science and technology have been a cornerstone of the U.S. defense enterprise for more than a century. The Defense Science Board (DSB) was created in the mid-1950s to leverage science and technology ...
Click to share on Facebook (Opens in new window) Click to share on X (Opens in new window) Click to email a link to a friend (Opens in new window) Click to print (Opens in new window) The St. Louis ...
Opinion
The Well News on MSNOpinion
Biotechnology is the new national security frontier - and America is falling behind
The United States has long led the global biomedical research and pharmaceutical development industry - but that leadership is eroding faster than many realize. A mix of U.S. policies that reward ...
– Vir Biotechnology (VIR) to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results